NCT07140328View on ClinicalTrials.gov

Evaluation of the Safety and Efficacy of HSK39004 Dry Powder Inhaler and HSK39004 Inhalation Suspension in Chinese Patients With Chronic Obstructive Pulmonary Disease (COPD)

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

April 24, 2025

Primary Completion Date

July 10, 2025

Study Completion Date

August 31, 2025

Conditions
Chronic Obstructive Lung Disease (COLD)
Interventions
DRUG

HSK39004 Dry Powder Inhaler -0.75mg BID

HSK39004 Dry Powder Inhaler: Inhale through the mouth, 0.75mg each time, twice a day； And HSK39004 Inhalation Suspension Simulants,administered via oral inhalation, Two units each time, twice daily ；

DRUG

HSK39004 Dry Powder Inhaler -1.5mg BID

HSK39004 Dry Powder Inhaler: Inhale through the mouth, 1.5mg each time, twice a day； And HSK39004 Inhalation Suspension Simulants,administered via oral inhalation, Two units each time, twice daily ；

DRUG

HSK39004 Inhalation Suspension -3mg BID

HSK39004 Inhalation Suspension: Inhale through the mouth, 3mg each time, twice a day； And HSK39004 Dry Powder Inhaler Simulants,administered via oral inhalation, 1 tablet each time, twice daily ；

DRUG

HSK39004 Placebo

HSK39004 Dry Powder Inhaler Simulants,administered via oral inhalation, 1 tablet each time, twice daily ； And HSK39004 Inhalation Suspension Simulants,administered via oral inhalation, Two units each time, twice daily ；

Trial Locations (1)

Unknown

Jiangsu Provincial People's Hospital, Nanchang

All Listed Sponsors
lead

Haisco Pharmaceutical Group Co., Ltd.

INDUSTRY